Replies to post #160757 on Biotech Values

[mcbio]

ARQL / MET

You sound like a pretty clear ARQL bear. Is that true, notwithstanding the current valuation and quite positive Phase 2 HCC data? Nothing wrong with that and respect that but just wanted to be clear.

[iwfal]

ARQL -

I'm quite sure Clark is talking about known / possible mutations of Met that may or may not be expressed in this cell line that would cause the Met to remain undetected due to the methods used.

I have to admit I was operating under the premise that the majority of oncogenic mutations to c-met were not yet known - either from a percentage of all oncogenic c-met mutations or from a percentage of of humans with a c-met mutated cancer. But your sentence above implies that the significant majority of mutations are known and listed - which is/would-be a surprise to me given how difficult it is to find something when you don't know what it looks like?

That said, apologies for causing a ruckus - debate is good, but didn't mean to cause division.